- Home
- BVFL vs TVRD Comparison
BVFL vs TVRD Comparison
Compare BVFL & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BVFL
- TVRD
- Stock Information
- Founded
- BVFL 1873
- TVRD 2017
- Country
- BVFL United States
- TVRD United States
- Employees
- BVFL N/A
- TVRD N/A
- Industry
- BVFL Savings Institutions
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- BVFL Finance
- TVRD Health Care
- Exchange
- BVFL Nasdaq
- TVRD Nasdaq
- Market Cap
- BVFL 160.4M
- TVRD 166.5M
- IPO Year
- BVFL N/A
- TVRD N/A
- Fundamental
- Price
- BVFL $15.76
- TVRD $25.61
- Analyst Decision
- BVFL
- TVRD Strong Buy
- Analyst Count
- BVFL 0
- TVRD 1
- Target Price
- BVFL N/A
- TVRD $39.00
- AVG Volume (30 Days)
- BVFL 25.0K
- TVRD 39.8K
- Earning Date
- BVFL 04-17-2025
- TVRD 05-21-2025
- Dividend Yield
- BVFL N/A
- TVRD N/A
- EPS Growth
- BVFL N/A
- TVRD N/A
- EPS
- BVFL 1.06
- TVRD N/A
- Revenue
- BVFL $38,257,000.00
- TVRD N/A
- Revenue This Year
- BVFL N/A
- TVRD N/A
- Revenue Next Year
- BVFL N/A
- TVRD N/A
- P/E Ratio
- BVFL $14.82
- TVRD N/A
- Revenue Growth
- BVFL 1.89
- TVRD N/A
- 52 Week Low
- BVFL $10.35
- TVRD $8.14
- 52 Week High
- BVFL $18.19
- TVRD $31.32
- Technical
- Relative Strength Index (RSI)
- BVFL 60.65
- TVRD N/A
- Support Level
- BVFL $15.64
- TVRD N/A
- Resistance Level
- BVFL $15.95
- TVRD N/A
- Average True Range (ATR)
- BVFL 0.39
- TVRD 0.00
- MACD
- BVFL 0.08
- TVRD 0.00
- Stochastic Oscillator
- BVFL 68.18
- TVRD 0.00
About BVFL BV Financial Inc.
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.